Looks like an exciting 2013 from the J.P. Morgan Healthcare Conference

32 of 40

Adelene Q. Perkins, President and CEO of Infinity Pharmaceuticals

Adelene Perkins, CEO of Infinity Pharmaceuticals, was in San Francisco discussing the biotech's clinical development plans for PI3K inhibitors, which include IPI-145 and IPI-443, after a trial setback forced a restructuring last year.